Related Experiment Video

Updated: May 10, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Long-term effects of recombinant human growth hormone therapy in children with Prader-Willi syndrome

Peter M Wolfgram1, Aaron L Carrel, David B Allen

  • 1Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin 53792-4108, USA.

Current Opinion in Pediatrics
|June 21, 2013
PubMed

Insights

Recombinant human growth hormone (hGH) therapy offers significant benefits for children with Prader-Willi syndrome (PWS), improving growth and metabolic health. Recent evidence suggests these advantages outweigh potential risks, supporting its use in PWS management.

Area of Science:

  • Pediatric Endocrinology
  • Genetics
  • Metabolic Disorders

Background:

  • Prader-Willi syndrome (PWS) is a complex genetic disorder affecting growth and metabolism.
  • Recombinant human growth hormone (hGH) is used to manage PWS symptoms.
  • Assessing the benefit-risk profile of hGH in PWS is crucial.

Purpose of the Study:

  • To review recent evidence on the efficacy and safety of hGH in children with PWS.
  • To conduct a benefit-risk analysis of hGH therapy for PWS.
  • To inform clinical decision-making regarding hGH treatment in PWS.

Main Methods:

  • Systematic review of recent studies on hGH therapy in pediatric PWS patients.
  • Analysis of reported outcomes including linear growth, body composition, and metabolic parameters.
  • Evaluation of adverse events, including sleep-disordered breathing and sudden death.

Main Results:

  • hGH therapy consistently improves stature, body composition, and metabolic markers in children with PWS.
  • Preliminary data suggest potential cognitive development benefits with hGH treatment.
  • Concerns regarding scoliosis progression and sudden death are not substantiated by recent findings; sleep-related cardiovascular function may improve.

Conclusions:

  • Recent evidence reinforces the benefits of hGH therapy in PWS, potentially including cognitive aspects.
  • hGH therapy can reduce morbidity and enhance function in children with PWS.
  • The benefits of hGH treatment for PWS appear to outweigh the associated risks.
Abstract

More Related Videos

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations05:04

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations

Published on: February 2, 2024

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...